A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction
| Autor: | Blayne Welk, Karen Ethans, Mary McKibbon, Sidney B. Radomski, Duane Hickling |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Canada medicine.medical_specialty Multiple Sclerosis Urology Urinary system 030232 urology & nephrology Pilot Projects Placebo law.invention 03 medical and health sciences 0302 clinical medicine Double-Blind Method Randomized controlled trial law medicine Humans Urinary Bladder Neurogenic Spinal cord injury Spinal Cord Injuries Aged Intention-to-treat analysis Urinary Bladder Overactive business.industry Multiple sclerosis Middle Aged medicine.disease Clinical trial Thiazoles Urodynamics Treatment Outcome Urinary Incontinence 030220 oncology & carcinogenesis Acetanilides Female Neurology (clinical) Mirabegron business medicine.drug |
| Zdroj: | Neurourology and Urodynamics. 37:2810-2817 |
| ISSN: | 0733-2467 |
| DOI: | 10.1002/nau.23774 |
| Popis: | AIMS To determine the effectiveness of mirabegron in patients with neurogenic lower urinary tract dysfunction. METHODS Randomized, double-blind, placebo-controlled study. Canadian patients with spinal cord injury (SCI) or multiple sclerosis (MS) with urinary symptoms and incontinence were recruited. Patients were randomized to mirabegron 25 mg (or an identical placebo) for 2 weeks at which point a dose escalation to mirabegron 50 mg (or an identical placebo) was maintained for 8 weeks. Urodynamics were performed before and after treatment. The primary outcome measure was maximum cystometric capacity (MCC). Intention to treat analysis and ANCOVA models (with adjustment for baseline values) were used and marginal means (MM) are reported; P-value |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text